Home » BOSTON SCIENTIFIC 'BUY' TARGET PRICE REDUCED
BOSTON SCIENTIFIC 'BUY' TARGET PRICE REDUCED
Analyst Glenn Novarro of Banc of America Securities maintains his "buy"
rating on Boston Scientific, while reducing his estimates for the company. The
target price has been reduced from $34 to $30.
Newratings
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
02May
-
07May
-
14May
-
23May
-
30May